Polyethylene Glycol 3350

Introduction Overview

Generic Name

polyethylene glycol 3350

Brand Name

MiraLAX

Dosage Form

Oral powder solution

Drug Class

Laxatives

Pharmacokinetics

Absorption:
Polyethylene glycol 3350 (PEG 3350) is minimally absorbed from the gastrointestinal tract when administered orally. Its molecular size and hydrophilicity limit its systemic absorption, allowing the majority of the administered dose to remain within the intestinal lumen. This characteristic is integral to its osmotic laxative action, as the compound holds water in the colon without systemic exposure. Clinical studies have consistently shown negligible serum levels post-oral administration, rendering systemic toxicity rare.

Distribution:
Due to minimal systemic absorption, polyethylene glycol 3350 does not undergo significant distribution into body tissues or plasma. Its action is localized within the gastrointestinal tract, predominantly the colon, where it exerts its therapeutic effects. This limited systemic distribution underpins the safety profile of PEG 3350, particularly in patients with normal gastrointestinal integrity.

Metabolism:
Polyethylene glycol 3350 is not metabolized by the body. It passes unchanged through the gastrointestinal tract. There is no involvement of hepatic enzymes in its metabolism, eliminating concerns of hepatic drug interactions or metabolic byproducts affecting efficacy or safety.

Elimination:
The elimination of PEG 3350 occurs exclusively through fecal excretion. As it holds water in the colon, it facilitates stool softening and promotes bowel movements without being chemically altered. Because of its lack of absorption and metabolism, renal or hepatic function does not significantly influence elimination. Clinical data indicate that PEG 3350 clears from the GI tract within 1 to 3 days after administration, commensurate with its onset of action.

Dosage Forms

Available Dosage Forms:
MiraLAX is formulated as an oral powder powder to be dissolved in water or other beverages prior to administration. The powder form allows flexible dosing and ease of consumption.

Dosages for Adults and Adolescents:
The recommended adult dose for occasional constipation is 17 grams of polyethylene glycol 3350 powder diluted in 8 ounces (approximately 240 mL) of beverage, taken orally once daily. This dose may be used for up to 7 days but should not exceed once daily dosing. Patients typically achieve a bowel movement within 1 to 3 days of initiating therapy.

Specific Patient Populations:
- Pediatric Dosing:
- Occasional Constipation: For children greater than 6 months, recommended dosing ranges from 0.5 to 1.5 g/kg/day. The initial dose often starts at 0.5 g/kg/day and can be titrated to effect, with a maximum dose limit of 17 g/day.
- Fecal Impaction: In children over 3 years old, dosing is 1 to 1.5 g/kg daily for 3 days, with a maximum of 100 g/day.
- Bowel Preparation: Children above 2 years may receive 1.5 g/kg/day up to a maximum 100 g/day for bowel cleansing prior to procedures.
- Elderly Population:
Although no specific dosing adjustments are universally mandated, clinical consideration is advised due to potential comorbidities and altered GI motility.

Clinical Guidelines and Administration:
MiraLAX powder should be measured with the dosing cap provided, dissolved completely in a beverage such as water, juice, soda, coffee, or tea, and consumed promptly to maintain efficacy. Repeated dosing beyond 7 days is not recommended without medical supervision due to potential risks of prolonged use.

Mechanism Of Action

Polyethylene glycol 3350 acts as an osmotic laxative by binding and retaining water molecules in the intestinal lumen. Its molecular structure, comprised of repeating ethylene glycol units, allows it to exert a strong osmotic effect by attracting and holding onto water, which leads to an increase in stool water content and volume. This augmentation in luminal hydration softens stools, making bowel movements easier and facilitating transit.

At the cellular and molecular level, PEG 3350 does not directly stimulate intestinal motility or secretory cells but indirectly promotes bowel movement by increasing stool liquidity and volume. The increased luminal water content stretches the colonic mucosa, stimulating peristalsis through mechanoreceptor activation, thereby propelling fecal matter through the colon.

Unlike stimulant laxatives, PEG 3350 is not associated with changes to electrolyte balance or damage to enterocytes, contributing to a favorable safety profile. Unlike fiber-based laxatives that rely on fermentation and gas production, PEG 3350’s action is purely osmotic and does not involve bacterial metabolism.

Clinically, these properties translate into a laxative effect that is effective within 1 to 3 days, suitable for treating uncomplicated occasional constipation. Additionally, PEG 3350 can be safely used in bowel preparation protocols to cleanse the colon prior to diagnostic procedures by inducing rapid and effective evacuation without significant systemic effects.

Pharmacological Actions

Acts as an osmotic laxative by retaining water in the intestinal lumen.
Increases stool water content and volume to facilitate bowel movements.
Softens stool consistency to relieve constipation and improve defecation.
Does not stimulate intestinal secretion or motility directly, reducing cramping.
Minimal systemic absorption allows for localized gastrointestinal action.
Does not alter electrolyte balance significantly, maintaining physiological stability.
Used for bowel preparation by inducing rapid colonic cleansing.
Exerts a favorable safety profile with low incidence of systemic side effects.
Does not promote dependence or damage intestinal mucosa even with short-term use.
Non-fermentable by intestinal bacteria, minimizing gas and bloating.
Effective in pediatric and adult patients for constipation relief.
Avoids stimulant laxative-associated risks such as electrolyte disturbances.
Compatible with prolonged use under medical supervision for chronic constipation.
Efficacious for both treatment of occasional constipation and bowel cleansing protocols.
Available in powder form facilitating versatile dosing and administration.

Therapeutic Or Clinical Uses

Management of occasional constipation in adults and children.
Treatment of acute constipation, providing relief within 1 to 3 days.
Facilitation of bowel movements in patients with irregular or infrequent stools.
Preparation of the bowel prior to colonoscopy or other colorectal procedures.
Use in pediatric populations for constipation and fecal impaction.
Adjunctive therapy in conditions where stool softening is beneficial.
Management of opioid-induced constipation when combined with other interventions.
Off-label usage for constipation associated with irritable bowel syndrome.
Temporary relief of constipation associated with pregnancy under medical guidance.
Safe option for constipation in elderly due to minimal systemic effects.
Prevention of straining and related complications such as hemorrhoids.
Support in chronic constipation management under clinical oversight.
Alternative laxative for patients intolerant to stimulant or fiber-based agents.
Bowel regimen component in patients with neurogenic bowel dysfunction.
Facilitation of stool passage in postoperative or immobile patients.

Side Or Adverse Effects

Bloating and abdominal gas due to increased luminal water content.
Mild to moderate stomach upset including cramping or discomfort.
Dizziness reported in some patients, likely secondary to dehydration or electrolyte changes.
Increased sweating as an uncommon systemic reaction.
Severe or bloody diarrhea indicating possible adverse reaction or overdose.
Rectal bleeding that may necessitate cessation of drug and medical evaluation.
Allergic reactions including hives, facial or throat swelling, and breathing difficulty.
Nausea and vomiting, particularly if underlying GI disorders are present.
Potential for electrolyte imbalance with prolonged or excessive use, although rare.
Risk of worsening symptoms in patients with undiagnosed bowel obstruction.
Possible interaction with pre-existing gastrointestinal mucosal diseases causing irritation.
Rare hypersensitivity reactions manifesting as rash or pruritus.
Rebound constipation if discontinued abruptly after prolonged use.
Risk of dehydration if fluid intake is inadequate during treatment.
Gastrointestinal disturbances more prevalent when used beyond recommended duration.

Precautions

Avoid use in patients with known bowel obstruction or intestinal blockage.
Use cautiously in patients with a history of ulcerative colitis or severe gastrointestinal diseases.
Not recommended for individuals with unexplained or persistent changes in bowel habits over 2 weeks.
Monitor patients with irritable bowel syndrome for symptom exacerbation upon initiation.
Exercise caution in patients with kidney disease due to potential electrolyte disturbances.
Avoid overuse or use beyond seven consecutive days without medical supervision.
Pregnancy category C: use only if potential benefit justifies potential risk to fetus.
Uncertain safety profile during breastfeeding; consult healthcare provider before use.
Patients with eating disorders should not use MiraLAX without medical advice.
Ensure adequate hydration to prevent dehydration and maintain therapeutic effect.
Monitor for signs of allergic reaction or severe diarrhea prompting immediate discontinuation.
Avoid simultaneous use with other laxatives unless advised by a healthcare professional.
Use caution in elderly patients, with monitoring for tolerability and hydration status.
Educate patients on correct dosing and preparation to ensure safety and efficacy.
Consider medical evaluation if constipation persists beyond one week of therapy.

Warnings

Risk of severe or life-threatening side effects if used in presence of bowel obstruction.
Potential for electrolyte imbalance and dehydration with excessive or prolonged use.
Possible allergic reactions requiring emergency treatment including anaphylaxis.
Do not use in patients with severe nausea, vomiting, or abdominal pain without medical evaluation.
Discontinue if severe, bloody diarrhea or rectal bleeding occur during treatment.
Not intended for chronic constipation management without physician oversight.
Avoid use in patients with undiagnosed severe gastrointestinal conditions.
Risk of masking serious underlying conditions if symptoms persist despite treatment.
Potential for misuse or overuse leading to dependence and worsened bowel function.
Use caution in pediatric patients, adhering strictly to dosing guidelines.
Patients should be advised against exceeding recommended daily dose.
Delayed effect (1-3 days) may lead to improper repeated dosing by patients seeking faster relief.
Pregnancy and lactation warnings due to insufficient safety data.
Withdrawal or abrupt cessation can lead to rebound constipation.
Consult healthcare provider before combining MiraLAX with other medications affecting bowel function.

Contraindication

Known hypersensitivity to polyethylene glycol or any component of MiraLAX formulation.
Presence of bowel obstruction or intestinal blockage.
History or presence of acute surgical abdomen.
Severe inflammatory bowel disease during exacerbations (e.g., ulcerative colitis flare).
Nausea and vomiting associated with severe abdominal pain of unknown origin.
Patients with suspected gastrointestinal perforation.
Individuals with ileus or impaired gastrointestinal motility.
Patients with known hypersensitivity reactions to polyethylene glycol-based products.
Children below 6 months of age without specific medical guidance.
Patients with dehydration or electrolyte imbalances without rehydration.
Concurrent usage with other osmotic laxatives not prescribed by a physician.
Patients noted to have bowel ischemia or compromised blood flow to intestines.
Severe renal impairment in the context of electrolyte disturbances.
Patients with anorexia or bulimia should not use without professional supervision.
Known hypersensitivity to any inactive ingredients in MiraLAX formulation.

Drug Interactions

Minimal pharmacokinetic interactions due to lack of systemic absorption; however, caution advised.
Co-administration with other laxatives may increase risk of dehydration and electrolyte imbalance.
Potentiation of effects with drugs causing electrolyte disturbances (e.g., diuretics, corticosteroids).
Concurrent use with drugs affecting gastrointestinal motility requires monitoring.
Potential interaction with medications requiring steady absorption timing due to altered GI transit.
May alter absorption of orally administered drugs due to changes in GI motility and fluid content.
Caution advised when used alongside nephrotoxic agents in patients with compromised renal function.
No significant interactions reported with common over-the-counter analgesics or antihistamines.
No known interactions with anticoagulants or antiplatelet agents.
Combination with stimulatory laxatives could increase risk of adverse GI effects.
Use with caution alongside medications absorbed in colon, as stool softening may affect bioavailability.
No significant documented interactions with antibiotics or antifungal agents.
Monitoring recommended when combined with medications that influence electrolyte balance.
Patients taking multiple medications should inform healthcare provider to evaluate additive effects.
Due to limited systemic absorption, clinically relevant drug interactions are rare.

Preparations Of The Drug

MiraLAX is formulated as a white, odorless, tasteless powder intended for oral solution.
Packaging includes bottles with molded dosing caps featuring internal dose measurement markers.
Powder is designed to be dissolved in 4 to 8 ounces of beverage such as water, juice, soda, coffee, or tea before administration.
No preservatives or flavoring agents are included, minimizing risk of hypersensitivity.
Stable at room temperature and should be stored away from moisture and heat.
Available in various bottle sizes suitable for short-term and extended use.
Generic polyethylene glycol 3350 formulations are also available under different brand names including GlycoLax, GaviLAX, ClearLax, and Purelax.
The product does not contain sodium, which is favorable for patients on sodium-restricted diets.
Manufactured under strict quality control to ensure consistent osmotic activity and safety profile.
Contains inactive ingredients to maintain powder consistency and promote dissolution in liquids.
No injectable or alternative dosage forms are commercially available; oral powder is the sole formulation.
Instructions emphasize immediate consumption after preparation and avoidance of storage of prepared solutions for later use.
Packaging includes detailed patient information on dosing, preparation, and precautions for safe use.
The product is non-habit forming and does not require tapering upon discontinuation.
Forms the basis of various bowel preparation regimens for radiological and endoscopic procedures.